Evommune signs $1.1bn licence deal with Hinova for EVO570
Evommune will pay $30m upfront, consisting of $20m in cash and $10m in pre-funded warrants for common shares.
Drug Development
PharmatrophiX and Circular partner on neurodegenerative drugs
GEBRO and Spektus sign collaboration for ActraFlex
FDA to review uniQure’s BLA for Huntington’s gene therapy
Inovio’s Voceryq receives FDA accelerated approval for RRP
Dren Bio raises $350m for dibotatug clinical development
Enthorin and Rumi sign agreement for FXS therapy
Formation Bio launches $600m drug development fund
